ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.488
-0.73%
Brent Oil
83.76
0.00%
Bitcoin
66,328.56
-0.91%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cellectis SA (CLLS)

  7. Cellectis SA (CLLS) Noticias

CLLS

Cellectis (CLLS)

Cellectis SA
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CLLS
FechaHoraFuenteTítuloSímboloCompañía
06/05/202405:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/05/202401:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:CLLSCellectis SA
02/05/202415:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerNASDAQ:CLLSCellectis SA
29/04/202415:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:CLLSCellectis SA
22/04/202415:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsNASDAQ:CLLSCellectis SA
10/04/202415:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsNASDAQ:CLLSCellectis SA
08/04/202415:30GlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingNASDAQ:CLLSCellectis SA
16/01/202415:30GlobeNewswire Inc.Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)NASDAQ:CLLSCellectis SA
22/12/202315:30GlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023NASDAQ:CLLSCellectis SA
17/11/202315:30GlobeNewswire Inc.Cellectis’ Shareholders Meeting to be Held on December 22, 2023NASDAQ:CLLSCellectis SA
15/11/202301:30GlobeNewswire Inc.Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNASDAQ:CLLSCellectis SA
06/11/202315:30GlobeNewswire Inc.Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023NASDAQ:CLLSCellectis SA
02/11/202315:30GlobeNewswire Inc.Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNASDAQ:CLLSCellectis SA
01/11/202315:30GlobeNewswire Inc.Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023NASDAQ:CLLSCellectis SA
01/11/202314:15AllPennyStocks.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNASDAQ:CLLSCellectis SA
01/11/202306:52Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:CLLSCellectis SA
01/11/202303:17Dow Jones NewsAstraZeneca to Invest $245 Million in Deal With CellectisNASDAQ:CLLSCellectis SA
01/11/202302:00GlobeNewswire Inc.Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZenecaNASDAQ:CLLSCellectis SA
31/10/202316:10Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:CLLSCellectis SA
31/10/202315:30GlobeNewswire Inc.Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:CLLSCellectis SA
12/10/202315:30GlobeNewswire Inc.Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)NASDAQ:CLLSCellectis SA
27/09/202315:30GlobeNewswire Inc.Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:CLLSCellectis SA
05/09/202315:32Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:CLLSCellectis SA
07/08/202316:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CLLSCellectis SA
07/08/202315:30GlobeNewswire Inc.Cellectis Provides Full Report for Second Quarter 2023 Financial ResultsNASDAQ:CLLSCellectis SA
03/08/202315:30GlobeNewswire Inc.Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023NASDAQ:CLLSCellectis SA
27/07/202315:30GlobeNewswire Inc.Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023NASDAQ:CLLSCellectis SA
12/07/202315:30GlobeNewswire Inc.Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of DirectorsNASDAQ:CLLSCellectis SA
29/06/202307:24Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CLLSCellectis SA
28/06/202315:30GlobeNewswire Inc.Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023NASDAQ:CLLSCellectis SA
 Showing the most relevant articles for your search:NASDAQ:CLLS

Su Consulta Reciente

NASDAQ
AAXAZXX
Morgan Stanley Finance L...
TG
KB7
Solventum
LSE
69DN
Sigma Fin.frn14
TG
WELM
Amundi Index Solutions
TSX
CIU.PR.C
CU
LSE
KJ84
Sg Issuer 32
LSE
SX86
Sg Issuer 32
POLO
GENSLRUSDT
Good Gensler
TSXV
BIG
Hercules Silver
BOV
ITUBS316
ITUBS316 Ex:30,22
COIN
SPLBGBP
AMEX
BINV
Brandes International ETF
BIT
UB2Y5S
UniCredit Bank
DGFX
GASUSDT
NEO Gas
COIN
DDFETH
NYSE
NVE
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados